In vivo, lapatinib-mediated inhibition of EGFR-PI3K-AKT signaling [106] or inhibition of the SCAP N-glycolysation [107] decreased tumor growth in EGFRvIII overexpressing GB models. The gene discussed is AKT1; the disease is neoplasm.